notificationsアラート設定
~
検索条件をクリア

アブストラクト

Title 乳がんの分子標的薬と免疫療法の進歩
Subtitle Theme 固形がんに対する免疫療法と分子標的治療の進歩 State of the art reviews and future perspectives
Authors 谷山智子1, 清水千佳子2
Authors (kana)
Organization 1国立国際医療研究センター病院乳腺・腫瘍内科, 2診療科長
Journal がん分子標的治療
Volume 18
Number 2
Page 162-168
Year/Month 2021 / 1
Article 報告
Publisher メディカルレビュー社
Abstract 「SUMMARY」約20年前に日本でトラスツズマブが承認されてから, HER2陽性乳がんの予後は大きく改善した. その後ラパチニブ, ペルツズマブ, トラスツズマブ エムタンシン(T-DM1), そしてこの2020年5月にはトラスツズマブ デルクステカン(DS-8201a)が国内で使用可能になっており, HER2陽性乳がんの治療の歴史は年々塗り替えられている. また, これまで分子標的薬がなかったとされる triple negative breast cancer でもHER2陰性生殖細胞系列BRCA遺伝子変異陽性乳がんに対して2018年にPARP阻害薬が, さらに翌年にはPD-L1陽性乳がんに対して抗PD-L1抗体が承認された. ホルモン陽性再発・転移性乳がんに対しては, mTOR阻害薬に加え, サイクリン依存性キナーゼ4/6阻害薬やPI3K阻害薬などの分子標的薬が次々と開発されており, 今後ますます乳がんの術前・術後, 再発・転移性がんに対する治療選択肢が広がり, それに従って治療体系が複雑化していくと考えられる.
Practice 臨床医学：一般
Keywords HER2陽性, HER2 positive, triple negative breast cancer, 遺伝性乳がん, hereditary breast cancer, ホルモン陽性, hormone positive
  • 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
download全文ダウンロード(8.03MB)

参考文献

  • 1) Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-92.
  • 2) Baselga J, Cortes J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012; 366: 109-19.
  • 3) Swain SM, Baselga J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015; 372: 724-34.
  • 4) Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Herceptin Adjuvant(HERA)Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005: 353: 1659-72.
  • 5) von Minckwitz G, Procter M, de Azambuja E, et al: APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med, 2017; 377: 122-31.
残りの29件を表示する
  • 6) Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with Iocally advanced, inflammatory, or early HER2-positive breast cancer(NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13: 25-32.
    pubmed
  • 7) Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer(NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016; 17: 791-800.
    pubmed
  • 8) Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68: 9280-90.
    pubmed
  • 9) Junttila TT, Li G, Parsons K, et al. Trastuzumab-DM1(T-DM1)retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011; 128: 347-56.
    pubmed
  • 10) Verma S, Miles D, Gianni L, et al; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367: 1783-91.
  • 11) von Minckwitz G, Huang CS, Mano MS, et al; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019; 380: 617-28.
    pubmed
  • 12) Harbeck N. Im SA, Barrios CH, et al. Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine(T-DM1)+pertuzumab versus trastuzumab+pertuzumab+taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer(EBC). J Clin Oncol. 2020; 38(15 Suppl.): abstr 500.
  • 13) Modi S, Saura C, Yamashita T, et al; DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020; 382: 610-21.
    pubmed
  • 14) Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355: 2733-43.
    pubmed
  • 15) Murthy RK, Loi S, Okines A, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020; 382: 597-609.
    pubmed
  • 16) Martin M, Holmes FA, Ejlertsen B, et al; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer(ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18: 1688-700.
  • 17) Saura C, Oliveira M, Feng YH, et al; NALA Investigators. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >= 2 HER2-Directed Regimens: Phase III NALA Trial. J Clin Oncol. 2020; 38: 3138-49.
  • 18) Rugo HS, Im S-A, Wright GLS, et al, SOPHIA primary analysis: A phase 3(P3)study of margetuximab(M)+chemotherapy(C)versus trastuzumab(T)+C in patients(pts) with HER2+metastatic(met)breast cancer(MBC)after prior anti-HER2 therapies(Tx). J Clin Oncol. 2019; 37(15 Suppl.): abstr 1000.
  • 19) Keung MYT, Wu Y, Vadgama JV. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. J Clin Med. 2019; 8: 435.
    pubmed
  • 20) Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017; 377: 523-33.
    pubmed
  • 21) Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018; 379: 753-63.
  • 22) Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019; 30: 397-404.
    pubmed
  • 23) Schmid P, Adams S, Rugo HS, et al; IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379: 2108-21.
  • 24) Schmid P, Cortes J, Pusztai L, et al; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020; 382: 810-21.
    pubmed
  • 25) Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016; 375: 1925-36.
    pubmed
  • 26) Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017; 35: 3638-46.
    pubmed
  • 27) Turner NC, Ro J, Andre F, et al: PALOMA3 Study Group. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015; 373: 209-19.
  • 28) Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017; 35: 2875-84.
    pubmed
  • 29) Llombart-Cussac A, Perez-Garcia JM, Bellet M, et al. PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor(ER)[+]/HER2[-]metastatic breast cancer. J Clin Oncol. 2020; 38(15 Suppl.): abstr 1007.
  • 30) Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer(MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018; 19: 904-15.
  • 31) Im SA, Lu YS, Bardia A, et al. Over-all Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019: 381: 307-16.
  • 32) Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012; 366: 520-9.
    pubmed
  • 33) Andre F, Ciruelos E, Rubovszky G, et al; SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380: 1929-40.
  • 34) Yardlev DA, Ismail-Khan RR, Melichar B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013; 31: 2128-35.
    pubmed
はじめての方へ
個人／法人会員登録のご案内